Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175444 | 0.85 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL5176252 | 0.85 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL5176623 | 0.85 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL3942498 | 0.76 | MEN1 (0.71) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL13103683 | 0.75 | EPHX2 (0.58) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL5176858 | 0.75 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL5176327 | 0.74 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C19TRPV1 | |
| SCHEMBL5175249 | 0.74 | MEN1 (0.49) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL5177337 | 0.73 | EPHX2 (0.52) | MEN1KMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL5674489 | 0.72 | EPHX2 (0.64) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | MEN1 2604/4885KMT2A 3176/4885CYP1A2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.